Background: Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity.
Cases Presentation: We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing.
Conclusions: Pazopanib is an active treatment in DT/AF. It is the first time this has been reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176486 | PMC |
| http://dx.doi.org/10.1186/2045-3329-3-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders.
Sci Rep
January 2025
Department of pharmacy, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, 450003, Henan, China.
Taste and smell disorders (TSDs) can induce diminished interest in food, inadequate nutrient intake, and emotional irregularities, particularly among cancer patients. Previous research found that the main culprits of TSD development in cancer patients are cytotoxic drugs such as taxol, fluorouracil, cyclophosphamide, and anthracycline-based drugs. The advent of targeted drugs such as vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) has significantly extended the survival time of cancer patients, and thus widely used in clinical practice.
View Article and Find Full Text PDFActivation of HSPA5 contributes to pazopanib-induced hepatotoxicity through l-ornithine metabolism pathway and endoplasmic reticulum stress.
J Pharm Pharmacol
November 2024
Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Objectives: The clinical application of Pazopanib (Paz) is often accompanied by hepatotoxicity. However, the mechanisms of hepatic toxicity induced by pazopanib are not entirely clarified.
Methods: Male C57BL/6J mice were treated with pazopanib every day for 2, 4, or 8 weeks.
STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.
Research (Wash D C)
November 2024
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003 Zhejiang, China.
Clear cell renal cell carcinoma (ccRCC) is a prevalent malignant tumor of the urinary system. While tyrosine kinase inhibitors (TKIs) are currently the first-line treatments for advanced/metastatic ccRCC, patients often develop resistance after TKI therapy. Lipid metabolic reprogramming, a hallmark of tumor progression, contributes to acquired drug resistance in various malignant tumors.
View Article and Find Full Text PDFSystematic multiomics analysis and in vitro experiments suggest that ITGA5 could serve as a promising therapeutic target for ccRCC.
Cancer Cell Int
November 2024
Department of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Shanghai, 200032, People's Republic of China.
Article Synopsis
- Integrin alpha 5 (ITGA5) is linked to cancer prognosis, yet its specific role in clear cell renal cell carcinoma (ccRCC) and its influence on tumor progression and the tumor microenvironment (TME) needed further investigation.
- Researchers used a machine learning model to analyze how ITGA5 expression impacts ccRCC, finding that higher levels are associated with adverse tumor characteristics and correlated with VHL mutations.
- The study suggests that high ITGA5 levels create an immunosuppressive TME by reducing CD8+ T cell infiltration, and proposes that combining ITGA5 inhibitors with VEGFR-targeted drugs could be an effective treatment strategy.
Exploring the therapeutic potential of Pongamia pinnata plant extract against skin cancer: In-silico and in-vitro study.
J Ethnopharmacol
January 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, P.O. Box, 9515, Jeddah, 21423, Saudi Arabia; Department of Biomedical Research, King Abdullah International Medical Research Center, P.O. Box 9515, Jeddah, 21423, Saudi Arabia.
Ethnopharmacological Relevance: Pongamia pinnata Linn belonging to the Fabaceae family, holds significance as a crucial remedy in herbal medicine.
Aim Of The Study: The present study aims to determine the anticancer and antioxidant properties of the plant extract.
Material And Methods: The methodology includes extraction of the leaf sample by soxhlet method followed by the phytochemical analysis of leaf extract.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!